| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 7987 | 2018 |
| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005 | 1121 | 2005 |
| Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. M Andersson, J Alvarez-Cermeno, G Bernardi, I Cogato, P Fredman, ... Journal of Neurology, Neurosurgery & Psychiatry 57 (8), 897-902, 1994 | 999 | 1994 |
| The genomic history of southeastern Europe I Mathieson, S Alpaslan-Roodenberg, C Posth, A Szécsényi-Nagy, ... Nature 555 (7695), 197-203, 2018 | 835 | 2018 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 683 | 2019 |
| The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review RA Marrie, S Reingold, J Cohen, O Stuve, M Trojano, PS Sorensen, ... Multiple Sclerosis Journal 21 (3), 305-317, 2015 | 628 | 2015 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 559 | 2019 |
| Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis MP Sormani, N De Rossi, I Schiavetti, L Carmisciano, C Cordioli, L Moiola, ... Annals of neurology 89 (4), 780-789, 2021 | 508 | 2021 |
| A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview RA Marrie, J Cohen, O Stuve, M Trojano, PS Sørensen, S Reingold, ... Multiple Sclerosis Journal 21 (3), 263-281, 2015 | 473 | 2015 |
| Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial RC Hermida, JJ Crespo, M Domínguez-Sardiña, A Otero, A Moya, ... European heart journal 41 (48), 4565-4576, 2020 | 471 | 2020 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 460 | 2016 |
| The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population MP Amato, E Portaccio, B Goretti, V Zipoli, L Ricchiuti, MF De Caro, F Patti, ... Multiple Sclerosis Journal 12 (6), 787-793, 2006 | 442 | 2006 |
| The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study C Solaro, G Brichetto, MP Amato, E Cocco, B Colombo, G D’aleo, ... Neurology 63 (5), 919-921, 2004 | 407 | 2004 |
| Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ... Multiple Sclerosis Journal 21 (8), 1013-1024, 2015 | 403 | 2015 |
| Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome E Millefiorini, C Gasperini, C Pozzilli, F D’andrea, S Bastianello, ... Journal of neurology 244, 153-159, 1997 | 389 | 1997 |
| Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes L Ruano, E Portaccio, B Goretti, C Niccolai, M Severo, F Patti, S Cilia, ... Multiple Sclerosis Journal 23 (9), 1258-1267, 2017 | 379 | 2017 |
| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 378 | 2020 |
| Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica A Ghezzi, R Bergamaschi, V Martinelli, M Trojano, MR Tola, E Merelli, ... Journal of neurology 251, 47-52, 2004 | 376 | 2004 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 370 | 2018 |
| Multiple sclerosis progression: time for a new mechanism-driven framework T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ... The Lancet Neurology 22 (1), 78-88, 2023 | 369 | 2023 |
Angelo GhezziDirettore Neurologia 2-Sclerosi MultiplaPotvrđena adresa e-pošte na asst-valleolona.it
